<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447472</url>
  </required_header>
  <id_info>
    <org_study_id>IMIMFTCL/MDMA/6</org_study_id>
    <secondary_id>AEMPS no.04-0013</secondary_id>
    <secondary_id>5R01DA017987</secondary_id>
    <nct_id>NCT01447472</nct_id>
  </id_info>
  <brief_title>-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms</brief_title>
  <official_title>Human Study of the Metabolic Changes Induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in the Metabolism of Dextromethorphan and Caffeine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study are:

        1. to evaluate the involvement of CYP2D6, CYP3A4 and CYP1A2 (through dextromethorphan and
           caffeine challenges), and catechol-O-methyltransferase (COMT)in MDMA metabolism

        2. to evaluate gender differences in the human pharmacology of MDMA

        3. to study the influence of some genetic polymorphisms (CYP2D6, COMT, SERT) in the effects
           and pharmacokinetics of MDMA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of dextromethorphan in plasma and urine.</measure>
    <time_frame>240 hours after MDMA dosing.</time_frame>
    <description>Blood samples and urine to determine dextromethorphan and dextrorphan concentrations until 240h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of caffeine in plasma and urine.</measure>
    <time_frame>24 hours after MDMA dosing.</time_frame>
    <description>Blood samples and urine to determine caffeine and theobromine concentrations until 240h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of MDMA and metabolites (influence of gender)</measure>
    <time_frame>48h after MDMA administration.</time_frame>
    <description>Determination of MDMA and metabolites concentrations in plasma and urine during 48h. Influence of gender male/female.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of MDMA and metabolites (influence of genetics)</measure>
    <time_frame>48h after MDMA administration.</time_frame>
    <description>Determination of MDMA and metabolites concentrations in plasma and urine during 48h. Influence of gene polymorphisms of CYP2D6, CYP3A4, COMT, SERT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of MDMA on physiological response.</measure>
    <time_frame>24h</time_frame>
    <description>Effects of MDMA on blood preassure, heart rate, temperature, pupil diameter, esophoria. Influence of gender and genetic polymorphisms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of MDMA on physiological response.</measure>
    <time_frame>24h</time_frame>
    <description>Effects of MDMA on subjective effects (feelings of intoxication, euphoria, bad effects etc) and psychological tests (VESSPA, ARCI). Influence of gender and genetic polymorphisms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Metabolism</condition>
  <condition>Interaction</condition>
  <arm_group>
    <arm_group_label>MDMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single dose of MDMA (1.5 mg/kg; range 75-100 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)</description>
    <arm_group_label>MDMA</arm_group_label>
    <other_name>Ecstasy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female adults, the recreational use of MDMA on at least ten occasions
             (two in the previous year), and the EM phenotype for CYP2D6 activity determined using
             dextromethorphan as a selective probe drug.

          -  Women had to present a regular menstrual cycle and not take oral contraceptives.

        Exclusion Criteria:

          -  Daily consumption &gt;20 cigarettes and &gt;4 standard units of ethanol in men (&gt;2 in women)

          -  Regular ingestion of medication in the month preceding the study

          -  Presence of major psychiatric disorders

          -  History of abuse or drug dependence (except for nicotine dependence)

          -  Psychiatric adverse reactions after MDMA consumption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magí Farre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet. 2011 May;50(5):319-29. doi: 10.2165/11584550-000000000-00000.</citation>
    <PMID>21456632</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol. 2008 Oct;28(5):523-9. doi: 10.1097/JCP.0b013e318184ff6e.</citation>
    <PMID>18794647</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDMA,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>CYP2D6, COMT,</keyword>
  <keyword>SERT, 5-HTTLPR, gender,</keyword>
  <keyword>dextromethorphan,</keyword>
  <keyword>caffeine.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

